HomeCompareTNGNQ vs ARCC

TNGNQ vs ARCC: Dividend Comparison 2026

TNGNQ yields 2000000.00% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TNGNQ wins by $4.879226400974806e+39M in total portfolio value
10 years
TNGNQ
TNGNQ
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full TNGNQ calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — TNGNQ vs ARCC

📍 TNGNQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTNGNQARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TNGNQ + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TNGNQ pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TNGNQ
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, TNGNQ beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TNGNQ + ARCC for your $10,000?

TNGNQ: 50%ARCC: 50%
100% ARCC50/50100% TNGNQ
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

TNGNQ
No analyst data
Altman Z
-61.9
Piotroski
1/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TNGNQ buys
0
ARCC buys
0
No recent congressional trades found for TNGNQ or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTNGNQARCC
Forward yield2000000.00%10.65%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$4.879226400974806e+39M$24.5K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$1.14
Total dividends collected$4.879195005460081e+39M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: TNGNQ vs ARCC ($10,000, DRIP)

YearTNGNQ PortfolioTNGNQ Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,373$532.74+$200.00MTNGNQ
2$3,738,731,768,458$3,738,517,757,009.35$12,608$279.46+$3738731.76MTNGNQ
3$65,315,062,866,930,490$65,311,062,423,938,240.00$13,809$142.90+$65315062866.92MTNGNQ
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$15,042$72.20+$1066400830062625.00MTNGNQ
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$16,341$36.27+$16272182796453826560.00MTNGNQ
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$17,732$18.18+$2.3205424011366188e+23MTNGNQ
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$19,231$9.10+$3.0927990661046884e+27MTNGNQ
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$20,851$4.55+$3.8524105697352695e+31MTNGNQ
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$22,605$2.28+$4.484688260147987e+35MTNGNQ
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$24,504$1.14+$4.879226400974806e+39MTNGNQ

TNGNQ vs ARCC: Complete Analysis 2026

TNGNQStock

Tengion, Inc. operates as a regenerative medicine company. The company focuses on discovering, developing, manufacturing, and commercializing a range of neo-organs or products composed of living cells with or without synthetic or natural materials that are implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. Its product portfolio includes Neo-Kidney Augment to prevent or delay dialysis by increasing renal function in patients with advanced chronic kidney disease; and Neo-Urinary Conduit, which is in Phase I clinical trial and used to replace the use of bowel tissue in bladder cancer patients requiring a non-continent urinary diversion after bladder removal surgery. The company has a license agreement with Children's Medical Center Corporation (CMCC) for the license of certain patent rights and intellectual property rights owned or controlled by CMCC related to tissue engineering technology. Tengion, Inc. was founded in 2003 and is headquartered in Winston-Salem, North Carolina. On December 29, 2014, Tengion, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Full TNGNQ Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this TNGNQ vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TNGNQ vs SCHDTNGNQ vs JEPITNGNQ vs OTNGNQ vs KOTNGNQ vs MAINTNGNQ vs HTGCTNGNQ vs GBDCTNGNQ vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.